Aileron Therapeutics (ALRN) News Today → AI's Next Magnificent Seven (From The Oxford Club) (Ad) Free ALRN Stock Alerts $3.19 +0.01 (+0.31%) (As of 10:07 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 6:02 AM | americanbankingnews.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $20,760.30 in StockJune 8 at 9:00 AM | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 6,291 Shares of StockJune 1, 2024 | americanbankingnews.comAileron Therapeutics (NASDAQ:ALRN) Upgraded to "Strong-Buy" at Brookline Capital ManagementJune 1, 2024 | marketbeat.comAileron Therapeutics (NASDAQ:ALRN) Rating Increased to Strong-Buy at Brookline Capital ManagementBrookline Capital Management upgraded shares of Aileron Therapeutics to a "strong-buy" rating in a research note on Thursday.May 29, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short InterestAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 256,900 shares, an increase of 89.0% from the April 30th total of 135,900 shares. Approximately 1.3% of the company's stock are sold short. Based on an average daily trading volume, of 90,500 shares, the days-to-cover ratio is presently 2.8 days.May 21, 2024 | marketbeat.comAileron Therapeutics (NASDAQ:ALRN) Releases Earnings Results, Misses Expectations By $0.72 EPSAileron Therapeutics (NASDAQ:ALRN - Get Free Report) released its earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.72).May 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | msn.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15, 2024 | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 10, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short InterestAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 135,900 shares, a growth of 213.1% from the April 15th total of 43,400 shares. Currently, 1.0% of the company's shares are sold short. Based on an average trading volume of 85,700 shares, the days-to-cover ratio is presently 1.6 days.May 6, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 3, 2024 | seekingalpha.comALRN Aileron Therapeutics, Inc.May 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 2, 2024 | finance.yahoo.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 2, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of StockMay 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $53,192.70 in StockAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the company's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the completion of the transaction, the insider now owns 1,799,711 shares of the company's stock, valued at approximately $8,908,569.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.May 1, 2024 | globenewswire.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)April 28, 2024 | marketbeat.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Rises By 22.9%Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily volume of 65,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company's shares are sold short.April 18, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:04 AM with a stated reason of "LULD pause."April 16, 2024 | investorplace.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 12, 2024 | globenewswire.comAileron Therapeutics Announces CEO TransitionFebruary 28, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:02 AM with a stated reason of "LULD pause."February 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 1, 2024 | finance.yahoo.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024January 30, 2024 | msn.comAileron Therapeutics Announces Director Nomination DetailsJanuary 30, 2024 | msn.comAileron Therapeutics Announces 2024 Annual Meeting PlansJanuary 30, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:01 AM with a stated reason of "LULD pause."December 27, 2023 | benzinga.comAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and DatesDecember 15, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%December 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy from Neutral at LadenburgDecember 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics dealNovember 5, 2023 | benzinga.comAileron Therapeutics Director Awarded $6K Worth of Stock OptionsNovember 1, 2023 | msn.comAileron gains after all-stock deal to acquire Lung TherapeuticsOctober 31, 2023 | finance.yahoo.comAileron Therapeutics Announces Acquisition of Lung TherapeuticsApril 4, 2023 | finance.yahoo.comBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' NowMarch 22, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN)March 14, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 3, 2023 | msn.comLooking Into Aileron Therapeutics's Recent Short InterestFebruary 23, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)February 22, 2023 | finance.yahoo.comCancer drugmaker down to 3 employees after trial failureFebruary 21, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%February 21, 2023 | seekingalpha.comAileron off 38% on plans to explore sale after setback for cancer candidateFebruary 21, 2023 | finance.yahoo.comAileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Clinton Backing Biden Replacement??? (Ad)According to Louis, it’s a near-certainty that just enough Republicans will abandon Trump to ensure his defeat. But Biden supporters shouldn’t break out the champagne, either… according to Louis’s shock finding, Biden is toast, too. This shocking video reveals exactly how. ALRN Media Mentions By Week ALRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALRN News Sentiment▼-0.020.74▲Average Medical News Sentiment ALRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALRN Articles This Week▼41▲ALRN Articles Average Week Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PDS Biotechnology News Unity Biotechnology News Cumberland Pharmaceuticals News Vaccinex News Mersana Therapeutics News Aquestive Therapeutics News Immutep News Enanta Pharmaceuticals News Atai Life Sciences News Nektar Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALRN) was last updated on 6/11/2024 by MarketBeat.com Staff From Our Partners[BUY ALERT] Our #1 A.I. Stock for AprilIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Behind the Markets | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored